

Mauro Cives

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3838525/publications.pdf>

Version: 2024-02-01

36
papers

1,509
citations

471061
17
h-index

344852
36
g-index

36
all docs

36
docs citations

36
times ranked

2310
citing authors

#	ARTICLE	IF	CITATIONS
1	Gastroenteropancreatic Neuroendocrine Tumors. <i>Ca-A Cancer Journal for Clinicians</i> , 2018, 68, 471-487.	157.7	378
2	Erdheim-Chester disease: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 1-11.	2.0	153
3	Radionuclide Therapy for Neuroendocrine Tumors. <i>Current Oncology Reports</i> , 2017, 19, 9.	1.8	113
4	Exosomes in melanoma: a role in tumor progression, metastasis and impaired immune system activity. <i>Oncotarget</i> , 2018, 9, 20826-20837.	0.8	97
5	Immune System Evasion as Hallmark of Melanoma Progression: The Role of Dendritic Cells. <i>Frontiers in Oncology</i> , 2019, 9, 1148.	1.3	90
6	The Tumor Microenvironment in Neuroendocrine Tumors: Biology and Therapeutic Implications. <i>Neuroendocrinology</i> , 2019, 109, 83-99.	1.2	87
7	Non-Melanoma Skin Cancers: Biological and Clinical Features. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5394.	1.8	83
8	Sirtuins and Cancer: Role in the Epithelial-Mesenchymal Transition. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-9.	1.9	62
9	Extracellular Vesicles and Epigenetic Modifications Are Hallmarks of Melanoma Progression. <i>International Journal of Molecular Sciences</i> , 2020, 21, 52.	1.8	38
10	SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand. <i>Oncotarget</i> , 2018, 9, 25355-25382.	0.8	34
11	Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) \geq 2 cm: Study Protocol for a Prospective Observational Study. <i>Frontiers in Medicine</i> , 2020, 7, 598438.	1.2	33
12	Novel immunotherapy strategies for treatment of neuroendocrine neoplasms. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 54-54.	1.5	29
13	DAXX mutations as potential genomic markers of malignant evolution in small nonfunctioning pancreatic neuroendocrine tumors. <i>Scientific Reports</i> , 2019, 9, 18614.	1.6	26
14	Circulating tumour cells and their association with bone metastases in patients with neuroendocrine tumours. <i>British Journal of Cancer</i> , 2019, 120, 294-300.	2.9	25
15	Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors. <i>Journal of Clinical Medicine</i> , 2020, 9, 3655.	1.0	23
16	NETs: organ-related epigenetic derangements and potential clinical applications. <i>Oncotarget</i> , 2016, 7, 57414-57429.	0.8	23
17	Osteotropism of neuroendocrine tumors: role of the CXCL12/CXCR4 pathway in promoting EMT <i>in vitro</i> . <i>Oncotarget</i> , 2017, 8, 22534-22549.	0.8	21
18	Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors. <i>JAMA Network Open</i> , 2022, 5, e220290.	2.8	21

#	ARTICLE	IF	CITATIONS
19	Parallelism of DOG1 expression with recurrence risk in gastrointestinal stromal tumors bearing KIT or PDGFRA mutations. BMC Cancer, 2016, 16, 87.	1.1	20
20	Reviewing the Osteotropism in Neuroendocrine Tumors: The Role of Epithelial-Mesenchymal Transition. Neuroendocrinology, 2016, 103, 321-334.	1.2	19
21	Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki-67 Is $\leq 10\%$?. Oncologist, 2021, 26, 294-301.	1.9	17
22	Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells. BMC Cancer, 2015, 15, 692.	1.1	16
23	A Phase II Study of Ibrutinib in Advanced Neuroendocrine Neoplasms. Neuroendocrinology, 2020, 110, 377-383.	1.2	15
24	An imbalance between Beclin-1 and p62 expression promotes the proliferation of myeloma cells through autophagy regulation. Experimental Hematology, 2014, 42, 897-908.e1.	0.2	13
25	Bone Metastases in Neuroendocrine Tumors: Molecular Pathogenesis and Implications in Clinical Practice. Neuroendocrinology, 2021, 111, 207-216.	1.2	13
26	Role of Bone Targeting Agents in the Prevention of Bone Metastases from Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 3022.	1.8	11
27	Local treatment for focal progression in metastatic neuroendocrine tumors. Endocrine-Related Cancer, 2019, 26, 405-409.	1.6	10
28	Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives. Cancer Treatment Reviews, 2021, 100, 102288.	3.4	9
29	The Role of Cytotoxic Chemotherapy in Well-Differentiated Gastroenteropancreatic and Lung Neuroendocrine Tumors. Current Treatment Options in Oncology, 2019, 20, 72.	1.3	7
30	Sensitivity and Specificity of the NETest: A Validation Study. Neuroendocrinology, 2021, 111, 580-585.	1.2	6
31	Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours. Current Treatment Options in Oncology, 2021, 22, 73.	1.3	6
32	Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3 rd -line treatment. World Journal of Gastroenterology, 2021, 27, 976-989.	1.4	3
33	The psychological impact of COVID-19 pandemic on patients with neuroendocrine tumors: Between resilience and vulnerability. Journal of Neuroendocrinology, 2021, 33, e13041.	1.2	3
34	Evaluating Risks and Benefits of Evolving Systemic Treatments of Neuroendocrine Tumors. JAMA Oncology, 2019, 5, 489.	3.4	2
35	Cell Fusion in Myeloma Marrow Microenvironment: Role in Tumor Progression. Critical Reviews in Oncogenesis, 2013, 18, 75-95.	0.2	2
36	The management of refractory carcinoid syndrome: challenges and opportunities ahead. Journal of Medical Economics, 2018, 21, 241-243.	1.0	1